Tianxu Du
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tianxu Du has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Enguang Bi
Department of Biochemistry and Molecular Biology School of Basic Medical Sciences Southern Medical University Guangzhou Guangdong China
1 shared publication - Handuo Wang
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, and
1 shared publication - Jiaxin Tang
Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China
1 shared publication - Jie Ren
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China
1 shared publication - Ling Jiang
Department of Hematology, Nanfang Hospital, and
1 shared publication - Qi Luo
School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China
1 shared publication
Latest Publications
- Open Access
- 2 December 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (3)
A fungi-derived cyclic peptide enhances Th9-mediated antitumor immunity by targeting ZAP70 and SREBP1
Adoptive cell therapy (ACT) relies on durable and functional T cells to mediate tumor clearance. Th9 cells are a metabolically fit CD4 + T cell subset with strong persistence but limited cytotoxicity. Here, we identified endomelipeptide A (EpA), a cyclic peptide isolated from Ganoderma lucidum –associated endophytic fungi, as a potent enhancer of Th9 cell differentiation. EpA promoted a cytotoxic Th9 phenotype with enhanced mitochondrial function and metabolic fitness. Mechanistically, EpA dually targeted ZAP70 and SREBP1, coupling T cell receptor signaling activation with lipid metabolism suppression. EpA-treated Th9 cells mediated robust, CD8 + T cell–dependent tumor control and enhanced the efficacy of human Th9 CAR T cell therapy in vivo. These findings establish EpA as a distinct cyclic peptide that reprograms Th9 cells and provides a potential approach to boost ACT efficacy.
- 2 December 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (3)
Open AccessA fungi-derived cyclic peptide enhances Th9-mediated antitumor immunity by targeting ZAP70 and SREBP1
Adoptive cell therapy (ACT) relies on durable and functional T cells to mediate tumor clearance. Th9 cells are a metabolically fit CD4 + T cell subset with strong persistence but limited cytotoxicity. Here, we identified endomelipeptide A (EpA), a cyclic peptide isolated from Ganoderma lucidum –associated endophytic fungi, as a potent enhancer of Th9 cell differentiation. EpA promoted a cytotoxic Th9 phenotype with enhanced mitochondrial function and metabolic fitness. Mechanistically, EpA dually targeted ZAP70 and SREBP1, coupling T cell receptor signaling activation with lipid metabolism suppression. EpA-treated Th9 cells mediated robust, CD8 + T cell–dependent tumor control and enhanced the efficacy of human Th9 CAR T cell therapy in vivo. These findings establish EpA as a distinct cyclic peptide that reprograms Th9 cells and provides a potential approach to boost ACT efficacy.